Transarterial Radioembolization Agents: a Review of the Radionuclide Agents and the Carriers.
Carrier molecules
Hepatocellular carcinoma
Microspheres
Radionucleotides
Transarterial radioembolization
Journal
Nuclear medicine and molecular imaging
ISSN: 1869-3474
Titre abrégé: Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101530478
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
received:
26
02
2021
revised:
16
06
2021
accepted:
29
06
2021
entrez:
23
8
2021
pubmed:
24
8
2021
medline:
24
8
2021
Statut:
ppublish
Résumé
Liver tumors, both primary and secondary to metastatic disease, remain a major challenge, with an increasing incidence. In this context, taking advantage of the dual blood supply of the liver, and the fact that liver tumors derive majority of their blood supply from the hepatic artery, intraarterial therapies are gaining popularity. Intraarterial liver-directed therapy (IALDT) is the option when the surgery is not feasible due to the number of metastases or for other reasons. Transarterial radioembolization (TARE) is a specific type of IALDT, where a carrier particle/microsphere is labeled with a radioactive substance and then is injected into hepatic artery for therapeutic purposes. As this field is rapidly evolving, with multiple agents being investigated and being introduced into clinical practice, it is hard for the practitioners and researchers to encompass all the available information concisely. This article aims to present a comprehensive review of the prominent TARE technologies.
Identifiants
pubmed: 34422126
doi: 10.1007/s13139-021-00709-3
pii: 709
pmc: PMC8322227
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
162-172Informations de copyright
© Korean Society of Nuclear Medicine 2021.
Déclaration de conflit d'intérêts
Conflict of InterestAysheh Alrfooh, Aditi Patel, and Sandeep Laroia declare that they have no conflict of interest.
Références
Eur J Nucl Med Mol Imaging. 2005 Aug;32(8):980-9
pubmed: 16032439
Pharmazie. 2005 Aug;60(8):583-7
pubmed: 16124400
J Labelled Comp Radiopharm. 2018 May 30;61(6):509-514
pubmed: 29462501
J Exp Clin Cancer Res. 2010 Jun 15;29:70
pubmed: 20550679
Eur J Nucl Med. 1999 Jul;26(7):699-704
pubmed: 10398817
Eur J Cancer. 2006 May;42(8):994-1003
pubmed: 16564689
Int J Radiat Oncol Biol Phys. 2009 Aug 1;74(5):1494-500
pubmed: 19157721
J Biomed Mater Res A. 2007 Sep 15;82(4):892-8
pubmed: 17335019
J Biomater Sci Polym Ed. 2005;16(5):549-61
pubmed: 16001715
J Hepatol. 2016 Nov;65(5):1017-1030
pubmed: 27395013
Appl Radiat Isot. 2000 Jan;52(1):63-8
pubmed: 10670924
Acta Biomater. 2013 Jan;9(1):4681-7
pubmed: 22947326
Curr Pharm Des. 2012;18(8):1023-31
pubmed: 22272822
Appl Radiat Isot. 2001 Jun;54(6):869-79
pubmed: 11300399
J Biomed Mater Res. 1998 Dec 15;42(4):617-25
pubmed: 9827687
J Nucl Med. 2014 Aug;55(8):1391-2
pubmed: 24925883
Korean J Radiol. 2007 Sep-Oct;8(5):418-28
pubmed: 17923785
Biomed Res Int. 2016;2016:1295329
pubmed: 27563661
Eur J Radiol. 2008 Sep;67(3):536-40
pubmed: 17826023
Appl Radiat Isot. 2005 Jun;62(6):915-8
pubmed: 15799869
Nucl Med Biol. 2010 Nov;37(8):861-7
pubmed: 21055615
J Hepatol. 2017 Mar;66(3):537-544
pubmed: 27773614
J Funct Biomater. 2018 Jan 26;9(1):
pubmed: 29373510
Cancer Biother Radiopharm. 2012 May;27(4):267-75
pubmed: 22489662
J Biomater Appl. 2002 Jan;16(3):227-41
pubmed: 11939457
Semin Nucl Med. 2016 Jul;46(4):324-39
pubmed: 27237442
J Vasc Interv Radiol. 2015 Jun;26(6):897-904.e2
pubmed: 25891507
Mol Clin Oncol. 2014 Nov;2(6):904-908
pubmed: 25279172
HPB (Oxford). 2014 Apr;16(4):336-41
pubmed: 23782387
J Labelled Comp Radiopharm. 2016 Jan;59(1):24-9
pubmed: 26691104
Eur J Pharm Biopharm. 2006 Jan;62(1):26-31
pubmed: 16154332
J Clin Oncol. 2005 May 1;23(13):2892-9
pubmed: 15860847
Nucl Med Biol. 1998 Oct;25(7):659-65
pubmed: 9804047
Biomed Res Int. 2018 Dec 31;2018:1435302
pubmed: 30687734
Int J Biol Macromol. 2020 Jul 15;155:1450-1459
pubmed: 31734365
Int J Biol Macromol. 2020 Jun 15;153:1035-1046
pubmed: 31794824
Phys Chem Chem Phys. 2011 Oct 21;13(39):17749-55
pubmed: 21887425
Drug Deliv. 2000 Oct-Dec;7(4):237-43
pubmed: 11195431
Int J Rad Appl Instrum B. 1991;18(7):783-90
pubmed: 1787088
Cancer. 2014 Oct 15;120(20):3111-21
pubmed: 24976177
Nucl Med Biol. 2001 Feb;28(2):197-204
pubmed: 11295430
Pharmacoepidemiol Drug Saf. 2011 Sep;20(9):956-63
pubmed: 21748824
Nucl Med Commun. 2002 Mar;23(3):237-42
pubmed: 11891481
Nanoscale. 2010 Dec;2(12):2607-13
pubmed: 20936240
In Vivo. 2018 May-Jun;32(3):567-573
pubmed: 29695562
Radiology. 1985 Jan;154(1):15-7
pubmed: 2981111
Med Sci Monit. 2017 Feb 13;23:796-800
pubmed: 28192388
Eur Radiol. 2019 Mar;29(3):1285-1292
pubmed: 30171360
Curr Med Chem. 2002 Jan;9(1):73-82
pubmed: 11860349
Cardiovasc Intervent Radiol. 2008 Nov-Dec;31(6):1124-32
pubmed: 18509704
Int J Rad Appl Instrum B. 1991;18(3):305-11
pubmed: 2071443
Radiat Res. 2014 Apr;181(4):416-24
pubmed: 24720750
Int J Rad Appl Instrum B. 1987;14(3):233-42
pubmed: 3667306
Drug Dev Ind Pharm. 2007 Feb;33(2):147-54
pubmed: 17454046
Bioresour Technol. 2014 May;160:129-41
pubmed: 24461334
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
World J Hepatol. 2015 Jun 28;7(12):1694-700
pubmed: 26140089
Nucl Med Commun. 2013 Jul;34(7):674-81
pubmed: 23587835
Liver Cancer. 2016 Jul;5(3):198-209
pubmed: 27493895
Gut Liver. 2016 May 23;10(3):332-9
pubmed: 27114433
Nucl Med Commun. 1994 Jul;15(7):545-53
pubmed: 7970432
Nucl Med Biol. 2019 Mar;70:46-52
pubmed: 30831342
Int J Nanomedicine. 2019 Apr 10;14:2591-2605
pubmed: 31040674
J Vasc Interv Radiol. 2014 Feb;25(2):240-7
pubmed: 24291001
Expert Opin Drug Deliv. 2013 Jun;10(6):799-810
pubmed: 23679932